Yes — modern silicone cohesive gel breast implants used in India are safe, CE-marked and CDSCO-approved devices that have undergone extensive long-term clinical evaluation. The cohesive ("gummy bear") gel does not migrate from the implant shell if it is disrupted. The most important current safety consideration is to use exclusively smooth-surfaced implants — avoiding macro-textured implants that are associated with BIA-ALCL (a rare lymphoma). SurgiPartner's partner hospitals exclusively use smooth, round, cohesive silicone gel implants from established, regulatory-approved manufacturers (Mentor, Motiva, Polytech, or equivalent). All implants carry individual serial numbers for lifelong tracking. The routine safety guidelines post-implant include: annual self-examination for sudden swelling, MRI surveillance every 5–10 years for implant integrity assessment, and prompt evaluation of any new breast changes. Call +91 9030053009 for a detailed safety discussion.

Choosing the right implant size is one of the most important decisions in breast augmentation — and one of the most common sources of dissatisfaction when done incorrectly. The correct approach begins with measuring your breast base width with callipers — this determines the maximum appropriate implant base diameter for your chest. Within the appropriate base diameter range, you then choose the projection profile (low, moderate, high, or ultra-high) based on how much forward projection you want — this determines the final cc volume. 3D computer imaging simulation (Crisalix or Vectra) allows you to preview the expected result with different implant sizes before committing to surgery. Trying on implant sizers in a fitted sports bra during the consultation also provides a realistic preview. The goal is an implant sized to YOUR anatomy — not a specific cup size number, which varies too much between brands to be a reliable target. SurgiPartner's surgeons use all of these tools at the pre-operative consultation — call +91 9030053009 to book a 3D simulation session in Hyderabad.

Modern silicone cohesive gel implants do not have a mandatory replacement schedule or an expiry date. They are designed to be lifetime devices. Replacement is only necessary if a complication develops — specifically capsular contracture (hardening), implant rupture, visible implant displacement, or personal preference for a size change. The cumulative rupture rate for modern implants is approximately 1% per year — meaning at 10 years, approximately 10% of implants may have some degree of shell compromise, though many are clinically silent (intracapsular rupture). The "replace every 10 years" recommendation is outdated — current guidelines recommend replacement only for symptomatic complications or confirmed rupture on imaging, not routinely. Surveillance MRI every 5–10 years is recommended to assess implant integrity in asymptomatic women. Call SurgiPartner on +91 9030053009 for implant follow-up assessment in Hyderabad.

Capsular contracture is the most common long-term complication of breast augmentation — occurring in approximately 5–15% of augmentation patients over 10 years. It refers to the abnormal hardening and tightening of the fibrous capsule that normally forms around any implant. As the capsule contracts, it compresses the implant — causing firmness, shape distortion, discomfort, and eventually significant pain and aesthetic deformity (Baker Grades III–IV). Prevention strategies that reduce capsular contracture risk include: exclusive use of smooth implants (lower contracture rate than textured); dual plane or submuscular placement; meticulous implant handling (minimal skin contact, Keller funnel insertion); use of antibiotic irrigant in the pocket; pocket irrigation with povidone-iodine; post-operative implant massage (controversial but widely practised); and early identification and treatment of subclinical infection. Treatment for symptomatic contracture: open capsulectomy (complete removal of the capsule) with implant exchange — this effectively resets the process, though contracture can recur. Call SurgiPartner on +91 9030053009 for assessment of existing capsular contracture.

Yes — the majority of women can breastfeed after breast augmentation with implants, particularly when the inframammary fold (under-breast) incision is used for implant placement. This incision is distant from the ductal system and does not disrupt milk-producing tissue. The periareolar incision carries a higher risk of ductal disruption and is associated with a modestly lower breastfeeding success rate. The implant itself — regardless of placement (subglandular, dual plane, or submuscular) — does not enter the breast glandular tissue and does not contact milk-producing structures. Studies show breastfeeding rates after augmentation are slightly lower than in the general population but the majority of women successfully lactate. If future breastfeeding is an important priority, discuss incision site selection and implant placement with your SurgiPartner plastic surgeon before surgery — call +91 9030053009.

Breast augmentation recovery: Days 1–3: most uncomfortable period — chest tightness (especially submuscular placement where the pectoralis muscle is stretched), moderate soreness managed with prescribed analgesia. Days 3–5: most patients are mobile and managing light activities. Week 1–2: return to desk work; avoid driving for 7–10 days. Week 4: transition from surgical bra to underwire bra; light lower-body exercise permitted. Week 6: upper body gym work and impact exercise resumed. Month 1–3: "Dropping and fluffing" — implants gradually descend from their initially high position into their final, natural resting position as the pectoral muscle (in submuscular placement) stretches and relaxes; the result continues to improve during this period. Month 3: 80–90% of the final result visible. Month 6: Final result assessed and photographed. Most patients are very pleasantly surprised by how quickly they feel comfortable and by how natural the result looks at 3–6 months.

Round implants have the same projection throughout their circumference — they create fullness evenly in the upper and lower breast poles. When a woman is upright, the natural shape of the breast (with more fullness in the lower pole) is created by gravity acting on the round implant. Round implants cannot rotate harmfully — even if they spin in the pocket, the result looks the same. They are available in multiple projection profiles (low to ultra-high). Anatomical (teardrop/shaped) implants have more fullness in the lower pole and less in the upper, mimicking the natural teardrop breast shape when standing. They are intended to create a more subtle, natural appearance — particularly appropriate for thin patients who want to avoid the "round, artificial look." The critical disadvantage is that anatomical implants must not rotate, as rotation creates visible breast asymmetry — this has historically required macro-texturing to hold position in the pocket, which carries BIA-ALCL risk. Modern approaches using smooth anatomical implants with precise pocket creation are emerging but not yet mainstream. For most patients, smooth round implants in dual plane placement provide excellent, natural, safe results — call SurgiPartner on +91 9030053009 for a personalised implant recommendation.

No — multiple large-scale, long-term epidemiological studies have consistently confirmed that breast implants do not increase the risk of breast cancer. This includes multiple Cochrane reviews and studies involving over 10,000 women followed for 10+ years. However, breast implants may make mammographic screening slightly more technically challenging — as implants partially obscure breast tissue on standard views. Radiographers use additional Eklund displacement views (pushing the implant back against the chest wall) to maximise tissue visualisation during mammography. Women with implants should continue standard breast cancer screening at the recommended schedule and inform their mammographer about their implants. Breast MRI (which provides excellent soft tissue visualisation and can assess implant integrity simultaneously) is increasingly used for surveillance in women with implants who are at elevated breast cancer risk. Call SurgiPartner on +91 9030053009 for any breast health concerns.

Breast augmentation cost in Hyderabad ranges from ₹1,20,000 to ₹2,80,000 for implant-based augmentation, depending on implant brand and volume, surgical technique, surgeon experience, and hospital facility. Implant-specific costs: Mentor, Motiva, or Polytech CE-certified implants (pair) cost ₹35,000–₹70,000 depending on size and brand. The remaining cost covers surgical team, anaesthesia, hospital day-care or overnight stay, surgical bra, post-operative medication, and follow-up appointments. Fat transfer augmentation: ₹1,00,000–₹2,00,000 depending on donor site liposuction volume and areas treated. Combined augmentation mastopexy (implants + lift): ₹2,00,000–₹3,80,000. As a cosmetic procedure, breast augmentation is not covered by health insurance in India. SurgiPartner provides complete, transparent all-inclusive pricing after clinical assessment — no hidden charges. Call +91 9030053009 for a free private consultation and 3D simulation in Hyderabad.